Provided by Tiger Trade Technology Pte. Ltd.

Amgen

429.88
-2.5400-0.59%
Post-market: 433.003.12+0.73%19:56 EDT
Volume:2.34M
Turnover:1.01B
Market Cap:231.48B
PE:26.70
High:431.85
Open:428.59
Low:426.00
Close:432.42
52wk High:447.03
52wk Low:269.77
Shares:538.48M
Float Shares:536.99M
Volume Ratio:1.13
T/O Rate:0.44%
Dividend:9.80
Dividend Rate:2.28%
EPS(TTM):16.10
EPS(LYR):14.23
ROE:91.47%
ROA:8.67%
PB:19.81
PE(LYR):30.21

Loading ...

Amgen Exec Says Expect a Meaningful Sequential Increase in Operating Expenses in the Third Quarter

THOMSON REUTERS
·
Aug 05

Amgen Exec Says Spent $500 Million in Q2 on Capital Expenditures, Driven by Investments Across United States Manufacturing Sites-Conf Call

THOMSON REUTERS
·
Aug 05

Amgen Q2 FY26 GAAP EPS Rises 65% to $4.37; Revenue Increases 10% to $10.1 Billion

Reuters
·
Aug 05

Amgen Inc Stock (AMGN) Closed Up by 3.03% on Aug 4: Key Drivers Unveiled

TradingKey
·
Aug 05

Amgen Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance

MT Newswires Live
·
Aug 05

GUIDANCE: (AMGN) Amgen Expects Full Year 2026 Revenue Range $38.2B - $39.4B, vs. FactSet Est of $37.74B

MT Newswires Live
·
Aug 05

Amgen Second-Quarter Sales Rise 9%, Profit Tops Street View

Reuters
·
Aug 05

Amgen Q2 Adj. EPS $6.29 Beats $5.62 Estimate, Sales $10.054B Beat $9.421B Estimate

Benzinga Earnings
·
Aug 05

Amgen Outlook FY Revenue USD 38,200-39,400 Million

THOMSON REUTERS
·
Aug 05

Amgen Inc: a Phase 1 Study of Amg 513 in Adults Living with Obesity Will Remain Ongoing

THOMSON REUTERS
·
Aug 05

Amgen Outlook FY Adjusted EPS USD 22.3-23.5

THOMSON REUTERS
·
Aug 05

Movement Alert|Amgen Rises 3.02% in Regular Trading, Q2 Earnings Report Draws Positive Market Reaction

Market Focus
·
Aug 05

Preview: Amgen Climbs Ahead of Earnings

Reuters
·
Aug 05

Amgen Extends Obesity Trial, Sharpening Its Long-Term Weight-Loss Bet

TIPRANKS
·
Aug 05

Amgen Declares Q3 2026 Dividend of R$ 0.31 Per Unit

Reuters
·
Aug 04

Stocks to Watch: Palantir, SpaceX, HSBC

Dow Jones
·
Aug 04

Amgen Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Aug 04

Amgen’s AMG 127 Trial Signals a New Push Into Type 2 Diabetes

TIPRANKS
·
Aug 04

KalÉO Announces License Agreement with Amgen for Auto-Injector Technology

THOMSON REUTERS
·
Aug 03

KalÉO: Financial and Other Terms of Agreement were not Disclosed

THOMSON REUTERS
·
Aug 03